- Datum01.07.2025
- Uhrzeit08:00 - 09:00 Uhr
- Veranstalter
XTB
Altan Cantürk
Moderator
Nanobiotix S.A. Reg.Shs (Spons. ADRs) o.N. Aktie
Verkaufen
Kaufen
Nanobiotix S.A. Reg.Shs (Spons. ADRs) o.N. Chart
Echtzeit-News zu diesem und anderen Unternehmen findest Du hier!
Live-Ticker Nanobiotix S.A. Reg.Shs (Spons. ADRs) o.N. Realtime-Kurs
| Handelsplatz | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| Stuttgart | VK | |||||
| Baader | VK | |||||
| Quotrix | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
4,50 %
Intraday
7,13 %
1 Woche
15,37 %
1 Monat
64,81 %
Seit Jahresbeginn
-5,40 %
1 Jahr
24,47 %
3 Jahre
Passender Service zu Nanobiotix S.A. Reg.Shs (Spons. ADRs) o.N.
Webinar zu Nanobiotix S.A. Reg.Shs (Spons. ADRs) o.N.
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)2,760-6,000
- Jahrestief / Hoch ($)2,820-5,760
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Nanobiotix S.A. Reg.Shs (Spons. ADRs) o.N.
Keine Dividenden verfügbar
Termine von Nanobiotix S.A. Reg.Shs (Spons. ADRs) o.N.
Keine aktuellen Termine
Beschreibung
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.
